Bellerophon Therapeutics Announces First Patient Treated with INOpulse® Inhaled Nitric Oxide Therapy for COVID-19

NEXT STORY
PhaseBio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Recent Business Highlights
PREV STORY
Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors

author_avatar
NASDAQ Market News

Sharps Compliance Reports Fiscal 2019 Third Quarter Results

author_avatar
NASDAQ Market News

ORYZON Publishes Paper in Journal of Clinical Oncology Demonstrating Relevance of Iadademstat in Leukemia

author_avatar
NASDAQ Market News